RenovoRx Faces Nasdaq Delisting, Appoints New CEO
Ticker: RNXT · Form: 8-K · Filed: Feb 23, 2024 · CIK: 1574094
| Field | Detail |
|---|---|
| Company | Renovorx, INC. (RNXT) |
| Form Type | 8-K |
| Filed Date | Feb 23, 2024 |
| Risk Level | high |
| Pages | 5 |
| Reading Time | 5 min |
| Key Dollar Amounts | $1.188 million, $2.5 m, $35 million, $500,000, $6.1 m |
| Sentiment | bearish |
Sentiment: bearish
Topics: delisting-notice, leadership-change, corporate-governance
TL;DR
**RenovoRx is on the brink of Nasdaq delisting for low stock price and just swapped CEOs, with Dr. Mark Theeuwes taking over from Shaun Bagai.**
AI Summary
RenovoRx, Inc. received a delisting notice from Nasdaq on February 16, 2024, due to its common stock closing below the minimum bid price of $1.00 for 30 consecutive business days. The company has until August 14, 2024, to regain compliance. Additionally, on February 23, 2024, RenovoRx announced the appointment of Dr. Mark Theeuwes as its new President and CEO, effective February 26, 2024, replacing Shaun Bagai, who will transition to Chief Operating Officer.
Why It Matters
The potential delisting from Nasdaq could severely impact RenovoRx's stock liquidity and investor confidence, while the CEO transition signals a strategic shift in leadership amidst these challenges.
Risk Assessment
Risk Level: high — The company faces delisting from Nasdaq, which is a significant risk to its public trading status and investor confidence.
Key Numbers
- $1.00 — Minimum Bid Price (Nasdaq's minimum bid price requirement for continued listing)
- 30 — Consecutive Business Days (Period RenovoRx's stock traded below $1.00, triggering the delisting notice)
- 180 — Calendar Days (Time granted by Nasdaq to regain compliance (until August 14, 2024))
Key Players & Entities
- RenovoRx, Inc. (company) — Registrant facing delisting and leadership change
- Nasdaq (company) — Exchange issuing delisting notice
- Dr. Mark Theeuwes (person) — New President and CEO of RenovoRx
- Shaun Bagai (person) — Former President and CEO, now Chief Operating Officer of RenovoRx
- $1.00 (dollar_amount) — Minimum bid price requirement for Nasdaq listing
- February 16, 2024 (date) — Date Nasdaq issued delisting notice
- August 14, 2024 (date) — Deadline for RenovoRx to regain Nasdaq compliance
- February 23, 2024 (date) — Date of CEO appointment announcement
- February 26, 2024 (date) — Effective date of Dr. Mark Theeuwes's appointment
FAQ
What is the primary reason RenovoRx, Inc. received a delisting notice from Nasdaq?
RenovoRx, Inc. received a delisting notice from Nasdaq because its common stock closed below the minimum bid price of $1.00 for 30 consecutive business days.
When did RenovoRx, Inc. receive the delisting notice from Nasdaq?
RenovoRx, Inc. received the delisting notice from Nasdaq on February 16, 2024.
What is the deadline for RenovoRx, Inc. to regain compliance with Nasdaq's listing rules?
RenovoRx, Inc. has until August 14, 2024, to regain compliance with Nasdaq's listing rules regarding the minimum bid price.
Who was appointed as the new President and CEO of RenovoRx, Inc.?
Dr. Mark Theeuwes was appointed as the new President and CEO of RenovoRx, Inc., effective February 26, 2024.
What is Shaun Bagai's new role at RenovoRx, Inc.?
Shaun Bagai, the former President and CEO, will transition to the role of Chief Operating Officer at RenovoRx, Inc.
Filing Stats: 1,369 words · 5 min read · ~5 pages · Grade level 13.2 · Accepted 2024-02-23 17:00:26
Key Financial Figures
- $1.188 million — e the Company's stockholders' equity of $1.188 million as reported in the Company's Quarterly
- $2.5 m — 2023 was below the required minimum of $2.5 million, and because, as of June 30, 2023
- $35 million — he market value of listed securities of $35 million or net income from continuing operation
- $500,000 — et income from continuing operations of $500,000 in the most recently completed fiscal y
- $6.1 m — ting in gross proceeds of approximately $6.1 million, which financing was additive to
Filing Documents
- form8-k.htm (8-K) — 41KB
- 0001493152-24-007693.txt ( ) — 209KB
- rnxt-20240223.xsd (EX-101.SCH) — 3KB
- rnxt-20240223_lab.xml (EX-101.LAB) — 33KB
- rnxt-20240223_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. RenovoRx, Inc. Date: February 23, 2024 By: /s/ Shaun Bagai Name: Shaun R. Bagai Title: Chief Executive Officer